LEIDEN, The Netherlands,
May 17, 2023 /PRNewswire/ -- Pharming
Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq:
PHAR) announces that at its Annual General Meeting of Shareholders
(AGM) held today, the proposal for a specific authorization for the
issuance of shares (or rights to acquire shares) to finance
mergers, acquisitions, or strategic alliances, was not put up for a
vote. All other proposals were approved.
The shareholders approved the proposal (agenda item 3.a) to
reappoint Paul Sekhri, Chair of the
Board, as Non-Executive Director for a period of one year. This
appointment aims to facilitate a prudent search process to find the
right candidate to succeed Mr. Sekhri as Chair of the Board of
Directors. Mr. Sekhri will resign from the Board upon appointment
of his successor. This will not exceed one year.
The shareholders approved the proposal to reappoint Deborah Jorn, MBA, the Vice-Chair of the Board
of Directors, as Non-Executive Director for a period of two years
(agenda item 3.b).
The proposal to grant specific authorization for the issuance of
shares, or rights to acquire shares, to finance mergers,
acquisitions or strategic alliances (agenda item 7.b) was withdrawn
at the start of the AGM, as the quorum requirement was not met for
the proposed authorization to exclude the pre-emptive rights of
existing shareholders.
The proposal for authorization to issue shares, or rights to
acquire shares, for general financing purposes (agenda item 7.a)
was approved by the shareholders.
A recording of the webcast, presentation slides from today's
AGM, and more details regarding agenda items are available on the
Company's website in the Investor Relations section.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
Inside Information
This press release relates to the disclosure of information
that qualifies, or may have qualified, as inside information within
the meaning of Article 7(1) of the EU Market Abuse
Regulation.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex
Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon
Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-group-reports-on-results-of-the-2023-annual-general-meeting-of-shareholders-301827463.html
